Missouri

Psychedelic trials in Missouri

22 registered trials has a study site in Missouri, and 1 is recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30

Facilities

Where the research happens in Missouri

Facility	City	Trials
Washington University School of Medicine	St Louis	8
University of Missouri	Columbia	2
Arch Clinical Trials, LLC	St Louis	1
Midwest Research Group - St. Charles Psychiatric Associates	Saint Charles	1
Kansas City VA Medical Center, Kansas City, MO	Kansas City	1
Washington University School of Medicine Healthy Mind Lab	St Louis	1
Midwest Research Group	Saint Charles	1
St. Charles Psychiatric Associates - Midwest Research Group	Saint Charles	1
Barnes-Jewish Hospital	St Louis	1
Washington University in St. Louis	St Louis	1
Clinical Site 126	O'Fallon	1
Clinical Site 139	St Louis	1
Washington University	St Louis	1

Stay told

When a trial opens in Missouri

All trials

Every trial with a Missouri site

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
Ketamine for Older Adults PilotNCT04504175 · Washington University School of Medicine	Completed	Phase 4	ketamine	5
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility TrialNCT05233566 · Washington University School of Medicine	Completed	Phase 3	ketamine	1
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case SeriesNCT06048263 · Washington University School of Medicine	Withdrawn	Phase 2 / Phase 3	ketamine	1
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
Ketamine to Prevent PPD After CesareanNCT04227704 · Washington University School of Medicine	Completed	Phase 3	ketamine	1
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	23
Psilocybin-Assisted Therapy as a Treatment for DepressionNCT07582120 · Washington University School of Medicine	Not yet recruiting	Phase 2	psilocybin	1
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
PET Synaptogenesis After Psilocybin In DEpression RecoveryNCT05601648 · Washington University School of Medicine	Withdrawn	Phase 2	psilocybin	1
KET-RO Plus RO DBT for Treatment Resistant DepressionNCT06138691 · Washington University School of Medicine	Completed	Phase 1	ketamine	1
Precision Functional Brain Mapping in PsilocybinNCT04501653 · Washington University School of Medicine	Completed	Early Phase 1	psilocybin	1
Treatment Resistant Depression (Pilot)NCT01179009 · Washington University School of Medicine	Completed	Not applicable	ketamine	1
Cognitive Recovery After Electroconvulsive Therapy and General AnesthesiaNCT02761330 · Washington University School of Medicine	Completed	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere